Abstract
Introduction
The treatment of psychiatric diseases is hardly straightforward; patients often try many different drug regimens and combinations in order to identify an optimal course of therapy. Although the long-term goal in treating psychiatric diseases is to halt disease progression and to prevent the onset of permanent damage, a more attainable step will be to individualize treatment for patients using available drugs.
Get the Answers You Need to Shape Your Strategy
Psychiatric franchises are transforming as industry players concede potential opportunities to others, capitalize on available opportunities, or challenge others for coveted opportunities. What are the major psychiatric franchises? What characteristics of the psychiatric industry make for a dynamic market? Few innovative psychiatric drugs are in development; however, psychiatric disease markets are substantial. Yet, big pharma' s single-minded focus on developing the next blockbuster drug concedes a large portion of pharmaceutical drug markets to midsize pharma companies. Which midsize companies have the largest psychiatric franchises, and how are they fi lling the market space conceded by big pharma? Identifying the genetic variations associated with psychiatric diseases will be essential in the development of drugs that provide personalized treatment options for patients. What pharmacogenomics-based agents are currently in development?
Scope
- Psychiatric diseases: overview and prevalence of the major psychiatric diseases in the seven major pharmaceutical markets (United States, Europe France, Germany, Italy, Spain, and the United Kingdom, and Japan).
- Worldwide psychiatric markets: a description of the psychiatric pharmaceutical industry and the top-selling psychiatric drug brands of 2005.
- Major psychiatric franchises: dominant big pharma, midsize pharma, and generics franchises.
- Psychiatric deals: a description of the recent license and collaboration deals in the psychiatric industry.
- Outlook: the impact of industry dynamics on pharmaceutical companies.
Mentioned in This Report-Companies
- Abbott Laboratories
- Affymetrix
- Albany Molecular Research
- Alza
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Carlsson Research
- Clinical Data
- Dr. Reddy' s Laboratories
- Eisai
- Eli Lilly
- Forest
- GlaxoSmithKline
- Ivax
- Johnson & Johnson
- Lundbeck
- Memory Pharmaceuticals
- Merck KGaA
- Mylan
- NeuroSearch
- Novartis
- Organon
- Otsuka
- Perlegen Sciences
- Pfi zer
- PGxHealth
- Reckitt Benckiser
- Sandoz
- Sanofi -Aventis
- Servier
- Shire Pharmaceuticals
- Solvay
- Targacept
- Teva Pharmaceuticals
- UCB
- Vanda Pharmaceuticals
- Verispan
- Vintage Pharmaceuticals
- Watson Pharmaceuticals
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Psychiatric Diseases
- Worldwide Psychiatric Markets-Top Brands
- Major Psychiatric Franchises
- Big Pharma Franchises
- AstraZeneca
- GlaxoSmithKline
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- Sanofi-Aventis
- Wyeth
- Midsize Pharma Franchises
- Generics Franchises
- Recent Psychiatric Deals
- Outlook
Figures
- 1. Total Prevalent Cases of Select Patient Populations, 2006
- 2. Blockbuster Psychiatric Drugs, 2005
- 3. Major Worldwide Psychiatric Franchises-Big and Midsize Pharma, 2005
- 4. Worldwide Generics Psychiatric Franchises, 2005
- 5. Genotype-Based Drug Doses for Antidepressants
Tables
- 1. Select Psychiatric Deals, 2005-2006
